Crucial Protein Based Drug Targets and Potential Inhibitors for Osteoporosis: New Hope and Possibilities

被引:8
作者
Chakraborty, Chiranjib [1 ]
Doss, C. George Priya [2 ]
机构
[1] Galgotias Univ, Sch Comp & Informat Sci, Dept Bioinformat, Greater Noida, India
[2] VIT Univ, Sch Biosci & Technol, Med Biotechnol Div, Vellore 632014, Tamil Nadu, India
关键词
Drug development; drug target; inhibitors; osteoporosis; protein based drug targets; CALCIUM-SENSING RECEPTOR; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; SALMON-CALCITONIN; IN-VIVO; PHARMACOKINETIC EVALUATION; STRUCTURAL CLASSIFICATION; THERAPEUTIC TARGETS; BIOCHEMICAL MARKERS; GENE POLYMORPHISMS;
D O I
10.2174/13894501113146660233
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Osteoporosis, a multifaceted bone disorder, is considered as a serious health problem throughout the world and the magnitude of diseased patients is increasing day by day. A number of successful therapeutics is available in the market for treatment. However, upon long-term administration, most of these drugs cause side-effects with some limitations. Henceforth, development of new therapeutic strategies can be a way to solve this problem as well as to develop cost effective and better tolerated therapies. Detailed understanding about the mechanistic action of the drug targets can be a great aid in the drug development process. Here in this review, we discussed the existing potential protein target class and their inhibitors related to osteoporosis. We have highlighted the existing potential protein drug targets, oestrogen receptor, calcium sensing receptor, P2Y receptor, activin receptor, calcitonin receptor, therapeutic manipulation of protease class such as cathepsin K, targeting WNT/ beta-catenin signaling and targeting RANK-RANKL signaling pathway, TNF inhibition through TNF receptor. We hope this detailed report will provide a better way of understanding towards the discovery and also for development of novel therapeutics.
引用
收藏
页码:1707 / 1713
页数:7
相关论文
共 99 条
[1]  
Adami S, 2006, 28 ANN M AM SOC BON
[2]   Minireview:: Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton [J].
Baron, Roland ;
Rawadi, Georges .
ENDOCRINOLOGY, 2007, 148 (06) :2635-2643
[3]   Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis [J].
Bolland, Mark J. ;
Avenell, Alison ;
Baron, John A. ;
Grey, Andrew ;
MacLennan, Graeme S. ;
Gamble, Greg D. ;
Reid, Ian R. .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 :289
[4]  
Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/jbmr.080901, 10.1359/JBMR.0809010]
[5]  
Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
[6]   Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women [J].
Caltabiano, Stephen ;
Dollery, Colin T. ;
Hossain, Mohammad ;
Kurtinecz, Milena T. ;
Desjardins, John P. ;
Favus, Murray J. ;
Kumar, Rajiv ;
Fitzpatrick, Lorraine A. .
BONE, 2013, 56 (01) :154-162
[7]   Bone morphogenetic proteins, their antagonists, and the skeleton [J].
Canalis, E ;
Economides, AN ;
Gazzerro, E .
ENDOCRINE REVIEWS, 2003, 24 (02) :218-235
[8]   Mechanisms of anabolic therapies for osteoporosis [J].
Canalis, Ernesto ;
Giustina, Andrea ;
Bilezikian, John P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (09) :905-916
[9]   Mortality after all major types of osteoporotic fracture in men and women: an observational study [J].
Center, JR ;
Nguyen, TV ;
Schneider, D ;
Sambrook, PN ;
Eisman, JA .
LANCET, 1999, 353 (9156) :878-882
[10]   Overexpression and purification of recombinant eel calcitonin and its phylogenetic analysis [J].
Chakraborty, C ;
Nandi, SS ;
Sarkar, B ;
Sinha, S .
PROTEIN AND PEPTIDE LETTERS, 2005, 12 (03) :263-269